Navigation Links
Gerresheimer has Passed the Turning Point
Date:10/15/2009

DUSSELDORF, Germany, October 15 /PRNewswire-FirstCall/ --

- Nine-Month Sales (Excluding Technical Plastics) 1.7% Down on Prior Year

- EBITDA Margin at High Level of 17.2%

- As Expected, Third Quarter Marked by Inventory Reductions by Large Customers

In the first nine months of the financial year (December 2008 - August 2009), Gerresheimer AG achieved sales of EUR 744.3m (prior year EUR 783.4m). Excluding the Technical Plastics business which has been sold, sales totaled EUR 714.9m, a reduction of 1.7% compared with the prior year. The corresponding operating margin (adjusted EBITDA) for the first three quarters continued on a high level at 17.9%. In Gerresheimer's key market of pharmaceutics, long-term demand is stable although some pharma customers have continued to reduce their inventory levels. The cosmetics sales which accounts for only 10% of total Group sales remained weak as expected. For the fourth quarter, Gerresheimer expects an increase in demand for pharma packaging and a slight recovery in the cosmetics business. It has accordingly quantified more precisely the outlook for the full financial year 2009. Organic growth in the fourth quarter will be offset by the weak dollar exchange rate. For the full year a small sales decline of between 1.5% and 2.5% and an operating margin (adjusted EBITDA) of around 18.5% are expected.

"The trend in the pharma business continues to be characterized by long-term growth. We are successfully pushing ahead with the consistent orientation of the Gerresheimer Group as a leading global partner for the pharma industry," says Dr. Axel Herberg, CEO of Gerresheimer AG. "Our latest investments - particularly in the growth market of pharma plastics - reflect this."

The importance of the Plastic Systems Division, which grew by over 5% at constant exchange rates during the first three quarters, is also shown by the two recent investments. In September 2009 Gerresheimer opened a new Research and Development Center for Medical Plastic Systems in the USA and a new Production Center for Plastic Packaging in Spain.

Group sales for the third quarter were as expected down on the prior year level of EUR 268.0m at EUR 242.6m. Excluding Technical Plastics, sales totaled EUR 236.9m, a decline of 5.3% against the prior year level. In the generally stable pharma segment some customers used the summer months to carry out further inventory reductions. In the cosmetics and life science segments, sales fell substantially because of weak demand. Operationally, Gerresheimer performed well in the third quarter. Adjusted EBITDA excluding Technical Plastics came to EUR 41.6m. Thanks to capacity and cost adjustments it was possible to hold the operating margin at the high level of 17.6%.

Outlook: the turning point has been passed

Thanks to rising demand and falling inventories, slight growth is expected for the pharma business in the fourth quarter. In the cosmetics business a slight improvement in demand is also evident, while in the Life Science Research segment no real recovery is foreseeable. For the financial year 2009, Gerresheimer has quantified more precisely the outlook last given in July 2009. For the full financial year the company assumes a slight sales decline of 1.5% to 2.5% and an operating margin (adjusted EBITDA) of around 18.5%. For the full financial year 2009 a total investment volume of around EUR 85 - 90m is expected.

"Thanks to our pharma orientation and very early capacity adjustments and cost reduction measures, our business is stable. We see indications that the turning point has already been passed in the third quarter," Herberg says.

About Gerresheimer

Gerresheimer employs around 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totaled EUR 1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

    Group Key Figures
    (IFRS; End of Q3: August 31; Financial Year end November 30)

    in EUR million           Q3      Q3  Change  Q1-Q3 Q1-Q3 Change  FY 2008
                            2009    2008      %   2009  2008      %

    Net sales              242.6   268.0   -9.5  744.3 783.4   -5.0  1.060.1

    Group net sales
     excluding Technical
     Plastics[1]           236.9   250.2   -5.3  714.9 727.4   -1.7    985.9
    Adjusted EBITDA[2]      42.0    50.3  -16.5  127.8 146.9  -13.0    206.4
    in % of net sales       17.3    18.8          17.2  18.8            19.5
    Adjusted EBITDA[2]
     excluding Technical
     Plastics               41.6    N/A[3]       128.1   N/A[3]        N/A[3]
    in % of net sales       17.6    N/A[3]        17.9   N/A[3]        N/A[3]

    Profit from
     operations (EBIT)      12.9   -10.9          33.9  22.5  +50.7     61.0
    Net income              -4.0   -22.8          -4.2 -14.7             4.5
    Adjusted net income[4]   7.9    16.5  -52.1   28.6  44.0  -35.0     61.4
    Earnings per share
     in EUR                 -0.11   -0.73         -0.15 -0.53            0.02
    Adjusted earnings        0.20    0.52 -61.5    0.83  1.34 -38.1      1.83
     per share[5] in EUR

    ---------------------------------

    1 Net sales of the recently divested Technical Plastics business (sold
      with effect from July 1, 2009) include the sales of the Technical
      Plastics tool business and amounted to EUR 74.2m in FY 2008

    2 Adjusted EBITDA: Earnings before income taxes, financial result,
      amortization of fair value adjustments, extraordinary depreciation,
      depreciation and amortization, restructuring expenses and one-off
      income and expenses

    3 The adjusted EBITDA of the Technical Plastics business of the
      comparative prior year period is not available due to the fact that the
      divestment was carried out in the course of the financial year and is
      therefore included in the Plastic Systems segment

    4 Adjusted net income: Consolidated profit before non-cash amortization
      of fair value adjustments, special effects from restructuring expenses,
      extraordinary depreciation, the balance of one-off income and expenses
      (including significant non-cash expenses) and the related tax effects

    5 Adjusted net income after minorities divided by 31.4m shares

    ---------------------------------

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com

SOURCE Gerresheimer AG


'/>"/>
SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Scientists Reveal Roadmap to Brain Health That Can Be Passed Down to Future Generations: Exercise, Omega-3, Folic Acid, Vitamin B6, and Vitamin B12
2. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
6. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
7. AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
10. West Pharmaceutical Services, Inc. Appoints New Director
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/15/2017)... PHILADELPHIA , July 15, 2017 Enterin Inc., ... compounds to treat Parkinson,s disease (PD), today announced the completion ... included new investors New Ventures III, as well as the ... "We are absolutely thrilled to have the support of New ... of our investors as validation of the potential of our ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... Hospital M&A activity ... HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the second quarter, ... and up 15% from the 20 announced deals in the year-ago second quarter. Only ...
(Date:7/21/2017)... , ... July 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... use of violence and aggression to solve problems and pleads with world leaders to be ... armed forces do not bring peace. He says there is a peaceful and positive way ...
(Date:7/21/2017)... ST. LOUIS, MO (PRWEB) , ... July 21, 2017 , ... ... are born knowing how to tie their shoes,” says Suzanne Tucker, Founder of St. ... created the Time-In Toolkit, which launches on Kickstarter on Monday, July 21st. , ...
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is ... clips in the FCPX timeline. This effect isolates horizontal and vertical lines of pixels ... contains either a rotating or flipping animation and can be changed using a drop-down ...
Breaking Medicine News(10 mins):